Other · developed by Skye Bioscience
SBI-100 is an ophthalmic emulsion administered as eyedrops at 0.5% and 1.0% concentrations. It is being studied in primary open angle glaucoma and ocular hypertension.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06144918 | Phase 2 | Primary Open Angle Glaucoma | Completed | SKYE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Ocular HypertensionPrimary Open Angle Glaucoma
Updated Nov 1, 2026. Something wrong or missing? Report it on the SKYE page.
See SKYE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SKYE catalysts and pipeline →